Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Current Deferred Revenue (2016 - 2025)

Tandem Diabetes Care's Current Deferred Revenue history spans 13 years, with the latest figure at $9.5 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 19.47% year-over-year to $9.5 million; the TTM value through Dec 2025 reached $9.5 million, down 19.47%, while the annual FY2025 figure was $9.5 million, 19.47% down from the prior year.
  • Current Deferred Revenue reached $9.5 million in Q4 2025 per TNDM's latest filing, down from $9.8 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $44.0 million in Q4 2023 to a low of $1.1 million in Q1 2024.
  • Average Current Deferred Revenue over 5 years is $15.3 million, with a median of $10.9 million recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: crashed 95.3% in 2024, then soared 897.91% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $10.2 million in 2021, then skyrocketed by 85.0% to $18.8 million in 2022, then soared by 133.55% to $44.0 million in 2023, then tumbled by 73.11% to $11.8 million in 2024, then fell by 19.47% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Current Deferred Revenue are $9.5 million (Q4 2025), $9.8 million (Q3 2025), and $10.5 million (Q2 2025).